Left ventricular filling patterns and its relation to left ventricular untwist in patients with type 1 diabetes and normal ejection fraction.

BACKGROUND: We evaluated young patients with type 1 diabetes (T1DM) who had normal left ventricular (LV) ejection fraction and used speckle tracking echocardiography to assess changes in LV untwisting. We used cardiac magnetic resonance imaging (MRI) to assess the LV filling patterns in these subjects. METHODS: We recruited 33 T1DM patients and 32 age-matched healthy controls (HC) into the study. Study participants underwent echocardiography, cardiac MRI and metabolic exercise testing. RESULTS: The early peak LV untwisting rate (E) was similar in T1DM and HC (-11.9 ± 4.6 0/cm/s vs -11.3 ± 4.7 0/cm/s, P=0.29) but the late peak LV untwisting rate (A) was significantly increased in T1DM (-6.2 ± 3 0/cm/s vs -4.9 ± 3.9 0/cm/s, P<0.05). The time to early peak untwisting rate was not different (50.9 ± 9.6% vs 48.4 ± 7.3%, P=0.12) but the time to late peak untwisting rate was significantly delayed in T1DM patients (80.4 ± 12.5% vs 72.7 ± 14.6%, P<0.05). The LV filling patterns demonstrated a significantly increased left atrial (LA) contribution to LV filling in T1DM. On linear regression peak late filling rate (r=0.60, P<0.000), trans-mitral A wave (r=0.25, P<0.05) and A' (r=0.30, P<0.01) were predictors of LA contribution to LV filling. CONCLUSION: We demonstrate for the first time using speckle tracking that LV untwisting rate E is preserved and untwisting rate A is increased and delayed in young patients with uncomplicated T1DM. The LA contribution to LV filling is increased in these patients and is directly related to increases in other indices of LA function like peak late filling rate, trans-mitral A wave and A'.

Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus.

BACKGROUND: Asymptomatic subjects with diabetes mellitus have an impaired cardiac energetics status that may play a significant role in the development of heart failure. In the present study, we assessed the role of microvascular dysfunction in the development of impaired cardiac energetics in subjects with type 1 diabetes mellitus. METHODS AND RESULTS: Twenty-five asymptomatic subjects with type 1 diabetes mellitus (mean age +/-1 SD 33+/-8 years) and 26 age-, sex-, and body mass index-matched healthy control subjects (32+/-8 years old) were recruited into the study. The type 1 diabetes mellitus subjects were divided into 2 age-matched groups (newly diagnosed [<5 years] and longer-duration [>10 years] diabetes) to assess the impact of microvascular disease. All subjects had an echocardiogram and an exercise ECG performed, followed by magnetic resonance spectroscopy and stress magnetic resonance imaging. Compared with healthy control subjects, the phosphocreatine/gamma-ATP ratio was reduced significantly both in subjects with longer-term (2.1+/-0.5 versus 1.5+/-0.4, P<0.000) and newly diagnosed (2.1+/-0.5 versus 1.6+/-0.2, P<0.000) diabetes. The phosphocreatine/gamma-ATP ratio was similar in newly diagnosed diabetes subjects and those with longer-term disease (1.6+/-0.2 versus 1.5+/-0.4, P=0.32). The mean myocardial perfusion reserve index in the longer-term type 1 diabetes mellitus subjects was significantly lower than in healthy control subjects (1.7+/-0.6 versus 2.3+/-0.4, P=0.005). On univariate analysis, there was no significant correlation of phosphocreatine/gamma-ATP ratio with myocardial perfusion reserve index (r=0.21, P=0.26). CONCLUSIONS: We demonstrate that young subjects with uncomplicated type 1 diabetes mellitus have impaired myocardial energetics irrespective of the duration of diabetes and that the impaired cardiac energetics status is independent of coronary microvascular function. We postulate that impairment of cardiac energetics in these subjects primarily results from metabolic dysfunction rather than microvascular impairment.

The heart metabolism: pathophysiological aspects in ischaemia and heart failure.

The morbidity and mortality of coronary heart disease and of heart failure remain unacceptably high despite major advances in their management. The main focus of treatment has been revascularisation for ischaemic heart disease and neuro-humoral modification for heart failure. There is an urgent need for new modalities of treatment to improve mortality and morbidity. Recently, there has been a great deal of interest in the role of disturbances in cardiac energetics and myocardial metabolism in the pathophysiology of both ischaemic heart disease and heart failure and of therapeutic potential of metabolic modulation. The myocardium is a metabolic omnivore, but mainly uses fatty acids and glucose for generation of Adenosine-5'-triphosphate (ATP). This review focuses on the key changes that occur to the metabolism of the heart in ischaemia and in heart failure and its effects on cardiac energetics.